Comparison of Hepatitis A, B, C, and D
Hepatitis A and E are transmitted fecal-orally and cause self-limited acute infections, while hepatitis B is transmitted parenterally/sexually and can cause chronic infection, and hepatitis D only occurs as a coinfection with hepatitis B, representing the most severe form of viral hepatitis.
Source of Infection
Hepatitis A
- Fecal-oral transmission through contaminated water, food (especially shellfish), or direct person-to-person contact 1, 2, 3
- Peak infectivity occurs during the 2-week period before jaundice onset, when stool viral concentration is highest 1
- Transmission occurs most frequently among household contacts and in extended family settings 2
- Children play a key role as they often have asymptomatic infections and serve as sources for adult transmission 2
- Foodborne outbreaks occur from contaminated food handlers or inadequately cooked foods 2
Hepatitis B
- Predominantly transmitted parenterally and sexually in travelers and general populations 3
- Blood and body fluid exposure through percutaneous injuries, sexual contact, or contaminated blood products 1
- Perinatal transmission from HBsAg-positive mothers to infants 4
- Occupational exposures through needlesticks, cuts with contaminated objects, or human bites 1
Hepatitis C
- Parenteral transmission through blood exposure 5
- Injection drug use is a major risk factor 1
- Less commonly transmitted sexually compared to hepatitis B 5
Hepatitis D
- Requires HBV coinfection as HDV needs the HBV envelope (HBsAg) to infect and egress from hepatocytes 5, 6
- Transmitted parenterally, predominantly through sexual contact or contaminated blood (drug use) or blood products 5
- Occurs as either acute coinfection with HBV or superinfection in chronic HBV carriers 5, 6
Clinical Course
Hepatitis A
- Self-limited disease that does not result in chronic infection or long-term liver disease 1
- Average incubation period of 28 days (range: 15-50 days) 1
- Signs and symptoms usually last <2 months 1
- 10%-15% of symptomatic persons have prolonged or relapsing disease lasting up to 6 months 1
- Persons with chronic liver disease who acquire hepatitis A are at increased risk for fulminant hepatitis 1
Hepatitis B
- Can be self-limiting or progress to chronic infection 3
- Clearance of infection is less likely in infants and older age groups 3
- Chronic infection defined as HBsAg positivity for longer than 6 months 7
- Can progress through immune-tolerant, immune-active, and inactive carrier phases 7
- Risk of cirrhosis and hepatocellular carcinoma in chronic infection 5
Hepatitis C
- Frequently progresses to chronic infection 5
- 5%-10% of acute cases remain anti-HCV negative even with prolonged follow-up 8
- Associated with development of cirrhosis and hepatocellular carcinoma in chronic cases 5
Hepatitis D
- Most severe form of chronic viral hepatitis when chronic HBV/HDV coinfection occurs 5, 6
- Associated with rapid and frequent progression to cirrhosis 6
- Increased risk of hepatic decompensation and hepatocellular carcinoma 5, 6
- Acute HDV infection can cause acute liver failure 6
Symptoms
Hepatitis A
- Produces symptoms of acute viral hepatitis among adolescents and adults 1
- Flu-like febrile illness followed by nausea, vomiting, abdominal pain, jaundice, and tender hepatomegaly 3
- Most young children who acquire hepatitis A are asymptomatic 9
Hepatitis B
- Ranges from asymptomatic infection to fulminant hepatitis 4
- Acute infection presents with flu-like symptoms, nausea, vomiting, abdominal pain, jaundice, and hepatomegaly 3
- Chronic infection may be asymptomatic until advanced liver disease develops 7
Hepatitis C
- Similar acute presentation to other viral hepatitides when symptomatic 3
- Many cases are asymptomatic during acute phase 8
- Chronic infection often asymptomatic until cirrhosis develops 5
Hepatitis D
- Clinical presentation similar to other viral hepatitides but typically more severe 5, 6
- Symptoms range from acute hepatitis to fulminant liver failure 6
- Chronic infection leads to more aggressive liver disease than HBV alone 5
Epidemiology
Hepatitis A
- Worldwide distribution with prevalence varying based on hygiene and sanitation conditions 9
- In areas with overcrowding and limited clean water, infection occurs almost universally early in life 9
- Historically highest rates in 11 western U.S. states, but dramatic decreases occurred after vaccine licensure 9
- Common among injection drug users (5%-19% of hepatitis A patients report injection drug use) 1
- Approximately 50% of patients have no identified source of infection 1, 2
Hepatitis B
- Major global public health problem 5
- Prevalence varies by geographic region, with high rates in Asia, Africa, and the Mediterranean 5
- Perinatal transmission is common in endemic areas 4
- Risk groups include healthcare workers, injection drug users, and those with multiple sexual partners 1
Hepatitis C
- Affects the same risk groups as HBV and HIV 5
- High prevalence among injection drug users 1
- Geographic distribution varies globally 5
Hepatitis D
- Worldwide, approximately 4-5% of individuals chronically infected with HBV are also coinfected with HDV 5
- High prevalence regions include parts of Africa, Asia, South America, and the Mediterranean 5
- Large proportion of HDV coinfections worldwide remain undetected 5
- Risk groups include people from endemic areas and those with parenteral exposure risks 5
Laboratory Diagnosis
Hepatitis A
- IgM anti-HAV is required to confirm acute HAV infection 2, 8
- IgM anti-HAV becomes detectable 5-10 days before symptom onset 2
- IgM anti-HAV declines to undetectable levels <6 months after infection in most patients 2
- Total anti-HAV (IgM and IgG) indicates past infection or immunity 2
- IgG anti-HAV appears early and remains detectable for life, providing lifelong protection 2
- HAV RNA can be detected in blood and stool during acute phase by nucleic acid amplification 2
Hepatitis B
- HBsAg positivity indicates current infection (acute or chronic) 7, 8
- IgM anti-HBc positive indicates acute infection 7, 8
- Chronic infection defined as HBsAg positivity for >6 months 7
- HBeAg positivity generally demonstrates high viral replication 7
- Anti-HBe positivity demonstrates lower viral replication 7
- HBV DNA measurement by PCR is crucial for assessing viral load and monitoring treatment 7, 4
- Anti-HBs antibodies indicate natural or post-vaccination immunity 5
- Quantitative anti-HBc is gaining attention as a biomarker for disease activity and HBV reactivation risk 5
- HBcrAg can indicate high viremia in treatment-naïve patients 5
Hepatitis C
- Anti-HCV positive, verified by supplemental test 8
- Serum aminotransferase levels >2.5 times upper limit of normal 8
- IgM anti-HAV negative and IgM anti-HBc negative (if done) or HBsAg negative 8
- Up to 20% of acute hepatitis C cases will be anti-HCV negative when reported 8
- Available serologic tests do not distinguish between acute and chronic infection 8
Hepatitis D
- All HBsAg-positive individuals should be screened for HDV at least once 5
- Detection of anti-HDV antibodies by immunoassays 5
- Testing for serum/plasma HDV RNA is needed to confirm ongoing HDV infection 5
- HDV antibody rapid diagnostic tests can be used in resource-limited settings 5
- HDV testing should be repeated with persistent risk factors or unexplained ALT elevation 5
- Variability exists in HDV RNA test performance due to differences in extraction methods and primer design 5
Key Clinical Pitfalls
- Do not assume hepatitis type based on clinical presentation alone—serologic testing is mandatory for differentiation 2
- For hepatitis B, aminotransferase changes are unreliable for assessing disease activity after transplantation—viral load and liver synthetic function markers are more valuable 4
- In hepatitis D, a large proportion of coinfections remain undetected—universal screening of all HBsAg-positive individuals is essential 5
- IgM anti-HBc alone has limited diagnostic value as it may be present in both acute and chronic HBV infection 5
- Anti-HCV does not distinguish acute from chronic infection—other causes of acute hepatitis must be excluded 8